Hydrogen sulfide pretreatment improves mitochondrial function in myocardial hypertrophy via a SIRT3-dependent manner

British Journal of Pharmacology

Volumn 175, Issue 8, 2018, Pages 1126-1145

  Meng, Guoliang ^a,b   Liu, Jieqiong ^b   Liu, Shangmin ^b   Song, Qiuyi ^a   Liu, Lulu ^a   Xie, Liping ^b   Han, Yi ^c   Ji, Yong ^b  

^a NANTONG UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; DYNAMIN I; HYDROGEN SULFIDE; MITOCHONDRIAL DNA; MITOCHONDRIAL PROTEIN; MITOFUSIN 1; MITOFUSIN 2; NUCLEIC ACID BINDING PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; SIRTUIN 3; SMALL INTERFERING RNA; SOD2 PROTEIN; SODIUM HYDROSULFIDE; SUPEROXIDE; TRANSCRIPTION FACTOR FKHRL1; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTIC CONSTRICTION; ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIAC INDEX; CARDIAC MUSCLE; CARDIAC MUSCLE CELL; CELL COUNT; CELL CULTURE; CELL FUNCTION; CELL FUSION; CELL SURFACE; CELL ULTRASTRUCTURE; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ECHOCARDIOGRAPHY; GENE DOSAGE; GENE SILENCING; HEART MITOCHONDRION; HEART SIZE; HEART VENTRICLE HYPERTROPHY; IMMUNOFLUORESCENCE; IN VIVO STUDY; LUCIFERASE ASSAY; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL PERMEABILITY; MITOCHONDRIAL RESPIRATION; MITOCHONDRIAL VOLUME; MOLECULAR INTERACTION; NEWBORN; NONHUMAN; OPTIC NERVE ATROPHY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRANSCRIPTION INITIATION; WESTERN BLOTTING; ANIMAL; CARDIOMEGALY; CHEMICALLY INDUCED; DRUG EFFECT; GENETICS; KNOCKOUT MOUSE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT; ULTRASTRUCTURE;

ANGIOTENSIN II; ANIMALS; CARDIOMEGALY; HYDROGEN SULFIDE; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE, KNOCKOUT; MITOCHONDRIA, HEART; MYOCARDIUM; MYOCYTES, CARDIAC; OXIDATIVE STRESS; RATS, SPRAGUE-DAWLEY; SIRTUIN 3;

EID: 85021839573     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13861     Document Type: Article

References (67)

1. Alexander SPH, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015) The Concise Guide to PHARMACOLOGY 2015/16: Enzymes. Br J Pharmacol 172: 6024–6109.
2. Ansari A, Rahman MS, Saha SK, Saikot FK, Deep A, Kim KH (2017). Function of the SIRT3 mitochondrial deacetylase in cellular physiology, cancer, and neurodegenerative disease. Aging Cell 16: 4–16.
3. Atkins K, Dasgupta A, Chen KH, Mewburn J, Archer SL (2016). The role of Drp1 adaptor proteins MiD49 and MiD51 in mitochondrial fission: implications for human disease. Clin Sci (Lond) 130: 1861–1874.
4. Burgoyne JR, Mongue-Din H, Eaton P, Shah AM (2012). Redox signaling in cardiac physiology and pathology. Circ Res 111: 1091–1106.
5. Cacanyiova S, Berenyiova A, Kristek F (2016). The role of hydrogen sulphide in blood pressure regulation. Physiol Res 65 (Suppl 3): S273–S289.
6. Chakraborty C, Doss CG (2013). Sirtuins family-recent development as a drug target for aging, metabolism, and age related diseases. Curr Drug Targets 14: 666–675.
7. Chen CJ, Fu YC, Yu W, Wang W (2013). SIRT3 protects cardiomyocytes from oxidative stress-mediated cell death by activating NF-κB. Biochem Biophys Res Commun 430: 798–803.
8. Chen H, Chomyn A, Chan DC (2005). Disruption of fusion results in mitochondrial heterogeneity and dysfunction. J Biol Chem 280: 26185–26192.
9. Cheung KG, Cole LK, Xiang B, Chen K, Ma X, Myal Y et al. (2015). Sirtuin-3 (SIRT3) protein attenuates doxorubicin-induced oxidative stress and improves mitochondrial respiration in H9c2 cardiomyocytes. J Biol Chem 290: 10981–10993.
10. Cogliati S, Frezza C, Soriano ME, Varanita T, Quintana-Cabrera R, Corrado M et al. (2013). Mitochondrial cristae shape determines respiratory chain supercomplexes assembly and respiratory efficiency. Cell 155: 160–171.
11. Curtis MJ, Bond RA, Spina D, Ahluwalia A, Alexander SP, Giembycz MA et al. (2015). Experimental design and analysis and their reporting: new guidance for publication in BJP. Br J Pharmacol 172: 3461–3471.
12. Feliers D, Lee HJ, Kasinath BS (2016). Hydrogen sulfide in renal physiology and disease. Antioxid Redox Signal 25: 720–731.
13. van Goor H, van den Born JC, Hillebrands JL, Joles JA (2016). Hydrogen sulfide in hypertension. Curr Opin Nephrol Hypertens 25: 107–113.
14. Hafner AV, Dai J, Gomes AP, Xiao CY, Palmeira CM, Rosenzweig A et al. (2009). Regulation of the mPTP by SIRT3-mediated deacetylation of CypD at lysine 166 suppresses age-related cardiac hypertrophy. Aging (Albany NY) 2: 914–923.
15. Hall AR, Burke N, Dongworth RK, Kalkhoran SB, Dyson A, Vicencio JM et al. (2016). Hearts deficient in both Mfn1 and Mfn2 are protected against acute myocardial infarction. Cell Death Dis 7: e2238.
16. He X, Zeng H, Chen JX (2016). Ablation of SIRT3 causes coronary microvascular dysfunction and impairs cardiac recovery post myocardial ischemia. Int J Cardiol 215: 349–357.
17. Hsu CP, Oka S, Shao D, Hariharan N, Sadoshima J (2009). Nicotinamide phosphoribosyltransferase regulates cell survival through NAD+ synthesis in cardiac myocytes. Circ Res 105: 481–491.
18. Hu C, Huang Y, Li L (2017). Drp1-dependent mitochondrial fission plays critical roles in physiological and pathological progresses in mammals. Int J Mol Sci 18 pii: E144.
19. Huang J, Wang D, Zheng J, Huang X, Jin H (2012). Hydrogen sulfide attenuates cardiac hypertrophy and fibrosis induced by abdominal aortic coarctation in rats. Mol Med Rep 5: 923–928.
20. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577–1579.
21. Koentges C, Bode C, Bugger H (2016a). SIRT3 in cardiac physiology and disease. Front Cardiovasc Med 3: 38.
22. Koentges C, Pfeil K, Meyer-Steenbuck M, Lother A, Hoffmann MM, Odening KE et al. (2016b). Preserved recovery of cardiac function following ischemia–reperfusion in mice lacking SIRT3. Can J Physiol Pharmacol 94: 72–80.
23. Koentges C, Pfeil K, Schnick T, Wiese S, Dahlbock R, Cimolai MC et al. (2015). SIRT3 deficiency impairs mitochondrial and contractile function in the heart. Basic Res Cardiol 110: 36.
24. Kong X, Wang R, Xue Y, Liu X, Zhang H, Chen Y et al. (2010). Sirtuin 3, a new target of PGC-1alpha, plays an important role in the suppression of ROS and mitochondrial biogenesis. PLoS One 5: e11707.
25. Lai YC, Tabima DM, Dube JJ, Hughan KS, Vanderpool RR, Goncharov DA et al. (2016). SIRT3–AMP-activated protein kinase activation by nitrite and metformin improves hyperglycemia and normalizes pulmonary hypertension associated with heart Failure with preserved ejection fraction. Circulation 133: 717–731.
26. Lazzeroni D, Rimoldi O, Camici PG (2016). From left ventricular hypertrophy to dysfunction and failure. Circ J 80: 555–564.
27. Le Page S, Niro M, Fauconnier J, Cellier L, Tamareille S, Gharib A et al. (2016). Increase in cardiac ischemia–reperfusion injuries in Opa1+/− mouse model. PLoS One 11: e0164066.
28. Li S, Yang G (2015). Hydrogen sulfide maintains mitochondrial DNA replication via demethylation of TFAM. Antioxid Redox Signal 23: 630–642.
29. Liang M, Jin S, Wu DD, Wang MJ, Zhu YC (2015). Hydrogen sulfide improves glucose metabolism and prevents hypertrophy in cardiomyocytes. Nitric Oxide 46: 114–122.
30. Liu J, Hao DD, Zhang JS, Zhu YC (2011). Hydrogen sulphide inhibits cardiomyocyte hypertrophy by up-regulating miR-133a. Biochem Biophys Res Commun 413: 342–347.
31. Liu Z, Han Y, Li L, Lu H, Meng G, Li X et al. (2013). The hydrogen sulfide donor, GYY4137, exhibits anti-atherosclerotic activity in high fat fed apolipoprotein E(−/−) mice. Br J Pharmacol 169: 1795–1809.
32. Lu F, Xing J, Zhang X, Dong S, Zhao Y, Wang L et al. (2013). Exogenous hydrogen sulfide prevents cardiomyocyte apoptosis from cardiac hypertrophy induced by isoproterenol. Mol Cell Biochem 381: 41–50.
33. Lu Y, Wang YD, Wang XY, Chen H, Cai ZJ, Xiang MX (2016). SIRT3 in cardiovascular diseases: Emerging roles and therapeutic implications. Int J Cardiol 220: 700–705.
34. Marín-García J, Akhmedov AT (2016). Mitochondrial dynamics and cell death in heart failure. Heart Fail Rev 21: 123–136.
35. Matsushima S, Sadoshima J (2015). The role of sirtuins in cardiac disease. Am J Physiol Heart Circ Physiol 309: H1375–H1389.
36. Maulik SK, Kumar S (2012). Oxidative stress and cardiac hypertrophy: a review. Toxicol Mech Methods 22: 359–366.
37. McDonnell E, Peterson BS, Bomze HM, Hirschey MD (2015). SIRT3 regulates progression and development of diseases of aging. Trends Endocrinol Metab 26: 486–492.
38. McGrath JC, Lilley E (2015). Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP. Br J Pharmacol 172: 3189–3193.
39. Meng G, Ma Y, Xie L, Ferro A, Ji Y (2015). Emerging role of hydrogen sulfide in hypertension and related cardiovascular diseases. Br J Pharmacol 172: 5501–5511.
40. Meng G, Xiao Y, Ma Y, Tang X, Xie L, Liu J et al. (2016). Hydrogen sulfide regulates Krüppel-like factor 5 transcription activity via specificity protein 1 S-sulfhydration at Cys664 to prevent myocardial hypertrophy. J Am Heart Assoc 5 pii: e004160.
41. Nadruz W (2015). Myocardial remodeling in hypertension. J Hum Hypertens 29: 1–6.
42. Oppikofer M, Kueng S, Gasser SM (2013). SIR–nucleosome interactions: structure–function relationships in yeast silent chromatin. Gene 527: 10–25.
43. Osborne B, Bentley NL, Montgomery MK, Turner N (2016). The role of mitochondrial sirtuins in health and disease. Free Radic Biol Med 100: 164–174.
44. Palmer CS, Elgass KD, Parton RG, Osellame LD, Stojanovski D, Ryan MT (2013). Adaptor proteins MiD49 and MiD51 can act independently of Mff and Fis1 in Drp1 recruitment and are specific for mitochondrial fission. J Biol Chem 288: 27584–27593.
45. Pillai VB, Bindu S, Sharp W, Fang YH, Kim G, Gupta M et al. (2016). Sirt3 protects mitochondrial DNA damage and blocks the development of doxorubicin-induced cardiomyopathy in mice. Am J Physiol Heart Circ Physiol 310: H962–H972.
46. Pillai VB, Sundaresan NR, Kim G, Gupta M, Rajamohan SB, Pillai JB et al. (2010). Exogenous NAD blocks cardiac hypertrophic response via activation of the SIRT3-LKB1-AMP-activated kinase pathway. J Biol Chem 285: 3133–3144.
47. Poulose N, Raju R (2015). Sirtuin regulation in aging and injury. Biochim Biophys Acta 1852: 2442–2455.
48. Pucci B, Villanova L, Sansone L, Pellegrini L, Tafani M, Carpi A et al. (2013). Sirtuins: the molecular basis of beneficial effects of physical activity. Intern Emerg Med 8 (Suppl 1): S23–S25.
49. Rodrigues PG, Leite-Moreira AF, Falcão-Pires I (2016). Myocardial reverse remodeling: how far can we rewind? Am J Physiol Heart Circ Physiol 310: H1402–HH422.
50. Sharp WW (2015). Dynamin-related protein 1 as a therapeutic target in cardiac arrest. J Mol Med (Berl) 93: 243–252.
51. Shen Y, Shen Z, Luo S, Guo W, Zhu YZ (2015). The cardioprotective effects of hydrogen sulfide in heart diseases: from molecular mechanisms to therapeutic potential. Oxid Med Cell Longev 2015: 925167.
52. Shi YX, Chen Y, Zhu YZ, Huang GY, Moore PK, Huang SH et al. (2007). Chronic sodium hydrosulfide treatment decreases medial thickening of intramyocardial coronary arterioles, interstitial fibrosis, and ROS production in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 293: H2093–H2100.
53. Shimizu I, Minamino T (2016). Physiological and pathological cardiac hypertrophy. J Mol Cell Cardiol 97: 245–262.
54. Southan C, Sharman JL, Benson HE, Faccenda E, Pawson AJ, Alexander SPH et al. (2016). The IUPHAR/BPS guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucleic Acids Res 44: D1054–D1068.
55. Sundaresan NR, Gupta M, Kim G, Rajamohan SB, Isbatan A, Gupta MP (2009). Sirt3 blocks the cardiac hypertrophic response by augmenting Foxo3a-dependent antioxidant defense mechanisms in mice. J Clin Inves 119: 2758–2771.
56. Szabo C (2017). Hydrogen sulfide, an enhancer of vascular nitric oxide signaling: mechanisms and implications. Am J Physiol Cell Physiol 312: C3–C15.
57. Tanno M, Kuno A, Horio Y, Miura T (2012). Emerging beneficial roles of sirtuins in heart failure. Basic Res Cardiol 107: 273.
58. Tham YK, Bernardo BC, Ooi JY, Weeks KL, McMullen JR (2015). Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets. Arch Toxicol 89: 1401–1438.
59. Walters JW, Amos D, Ray K, Santanam N (2016). Mitochondrial redox status as a target for cardiovascular disease. Curr Opin Pharmacol 27: 50–55.
60. Wu D, Si W, Wang M, Lv S, Ji A, Li Y (2015). Hydrogen sulfide in cancer: friend or foe? Nitric Oxide 50: 38–45.
61. Xie L, Feng H, Li S, Meng G, Liu S, Tang X et al. (2016). SIRT3 mediates the antioxidant effect of hydrogen sulfide in endothelial cells. Antioxid Redox Signal 24: 329–343.
62. Yang F, Liu Z, Wang Y, Li Z, Yu H, Wang Q (2014). Hydrogen sulfide endothelin-induced myocardial hypertrophy in rats and the mechanism involved. Cell Biochem Biophys 70: 1683–1686.
63. Yao Y, Yang Y, Zhu WG (2014). Sirtuins: nodes connecting aging, metabolism and tumorigenesis. Curr Pharm Des 20: 1614–1624.
64. Yu W, Gao B, Li N, Wang J, Qiu C, Zhang G et al. (2016). Sirt3 deficiency exacerbates diabetic cardiac dysfunction: role of Foxo3A-Parkin-mediated mitophagy. Biochim Biophys Acta pii: S0925-4439(16)30274-5.
65. Yue Z, Ma Y, You J, Li Z, Ding Y, He P et al. (2016). NMNAT3 is involved in the protective effect of SIRT3 in Ang II-induced cardiac hypertrophy. Exp Cell Res 347: 261–273.
66. Zhang X, Ren X, Zhang Q, Li Z, Ma S, Bao J et al. (2016). PGC-1α/ERRα-Sirt3 pathway regulates DAergic neuronal death by directly deacetylating SOD2 and ATP synthase β. Antioxid Redox Signal 24: 312–328.
67. Zhou X, Zhao L, Mao J, Huang J, Chen J (2015). Antioxidant effects of hydrogen sulfide on left ventricular remodeling in smoking rats are mediated via PI3K/Akt-dependent activation of Nrf2. Toxicol Sci 144: 197–203.